Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for OV329 (GABA-AT inhibitor) in Epilepsy. The expected timing is based on the latest available company guidance and may change.
8/9/23- Completed SAD portion. Presentation at AES '23. 5/13/25- Topline Ph1 data in Q3 2025. 10/3/25- Topline data reported. Advance into Ph2a in Q2 2026 and complete in mid-2027. 11/12/25:- Ph1 showed strong efficacy and safety; late-breaking AES 2025 poster; Ph2a starts Q2 2026. 03/18/26:- 7 mg Ph1 cohort safe; Ph2 FOS trial Q2 2026; PPR study Q3 2026; TSC/IS trials 2026-2027. 05/12/26:- 9 mg cohort also safe with favorable PK; Ph2 FOS and PPR patient studies advancing as planned. 08/13/26:- Phase 2 FOS study initiated and will complete in H2 2027. Photosensitivity study results are expected near year-end 2026.
Verification
Confirm timing and program details against the company announcement or filing.